Translationally controlled tumor protein induces mitotic defects and chromosome missegregation in hepatocellular carcinoma development

Hepatology

Volumn 55, Issue 2, 2012, Pages 491-505

  Chan, Tim Hon Man ^a,b   Chen, Leilei ^a,b   Liu, Ming ^a   Hu, Liang ^a   Zheng, Bo Jian ^b   Poon, Vincent Kwok Man ^b   Huang, Pinzhu ^c   Yuan, Yun Fei ^c   Huang, Jian Dong ^b   Yang, Jie ^b   Tsao, George Sai Wah ^b   Guan, Xin Yuan ^a,b,c  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHD1L PROTEIN; CHROMODOMAIN HELICASE DNA BINDING PROTEIN 1 LIKE PROTEIN; CYCLIN DEPENDENT KINASE 1; DNA BINDING PROTEIN; PROTEIN; TRANSLATIONALLY CONTROLLED TUMOR PROTEIN; TUMOR PROTEIN; TYROSINE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARCINOGENICITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MITOSIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; TUMOR CELL;

EID: 84863011661     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24709     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25: 143-154.
3. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003; 39: 1076-1084.
4. Chen L, Chan TH, Guan XY. Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma. Acta Pharmacol Sin 2010; 31: 1165-1171.
5. Ma NF, Hu L, Fung JM, Xie D, Zheng BJ, Chen L, et al. Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma. HEPATOLOGY 2008; 47: 503-510.
6. Chen L, Hu L, Chan TH, Tsao GS, Xie D, Huo KK, et al. Chromodomain helicase/adenosine triphosphatase DNA binding protein 1-like (CHD1L) gene suppresses the nucleus-to-mitochondria translocation of nur77 to sustain hepatocellular carcinoma cell survival. HEPATOLOGY 2009; 50: 122-129.
7. Chen M, Huang JD, Hu L, Zheng BJ, Chen L, Tsang SL, et al. Transgenic CHD1L expression in mouse induces spontaneous tumors. PLoS One 2009; 4: e6727.
8. Zhu WL, Cheng HX, Nan N, Liu DL, Zhu WX, Fan BL, Duan FC. Messenger RNA expression of translationally controlled tumor protein (TCTP) in liver regeneration and cancer. Anticancer Res 2008; 28: 1575-1580.
9. Slaby O, Sobkova K, Svoboda M, Garajova I, Fabian R, Hrstka R, et al. Significant overexpression of Hsp110 gene during colorectal cancer progression. Oncol Rep 2009; 21: 1235-1241.
10. Gachet Y, Tournier S, Lee M, Lazaris-Karatzas A, Poulton T, Bommer UA. The growth-related, translationally controlled protein P23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle. J Cell Sci 1999; 112: 1257-1271.
11. Tuynder M, Fiucci G, Prieur S, Lespagnol A, Géant A, Beaucort S, et al. Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci U S A 2004; 101: 15364-15369.
12. Chen L, Chan TH, Tuan YF, Hu L, Huang J, Ma S, et al. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest 2010; 120: 1178-1191.
13. Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995; 23: 4878-4884.
14. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005; 21: 2933-2942.
15. Clute P, Pines J. Temporal and spatial control of cyclin B1 destruction in metaphase. Nat Cell Biol 1999; 1: 82-87.
16. Dunphy WG. The decision to enter mitosis. Trends Cell Biol 1994; 4: 202-207.
17. Seong YS, Min C, Li L, Yang JY, Kim SY, Cao X, et al. Characterization of a novel cyclin-dependent kinase 1 inhibitor, BMI-1026. Cancer Res 2003; 63: 7384-7391.
18. Niiya F, Xie X, Lee KS, Inoue H, Miki T. Inhibition of cyclin-dependent kinase 1 induces cytokinesis without chromosome segregation in an ECT2 and MgcRacGAP-dependent manner. J Biol Chem 2005; 280: 36502-36509.
19. Potapova TA, Daum JR, Pittman BD, Hudson JR, Jones TN, Satinover DL, et al. The reversibility of mitotic exit in vertebrate cells. Nature 2006; 440: 954-958.
20. Lindqvist A, Källström H, Lundgren A, Barsoum E, Rosenthal CK. Cdc25B cooperates with Cdc25A to induce mitosis but has a unique role in activating cyclin B1-Cdk1 at the centrosome. J Cell Biol 2005; 171: 35-45.
21. Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G. Phosphorylation and activation of human cdc25-C by cdc2-cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J 1993; 12: 53-63.
22. Izumi T, Maller JL. Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. Mol Biol Cell 1993; 4: 1337-1350.
23. Vassilev LT, Tovar C, Chen S, Knezevic D, Zhao X, Sun H, et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci U S A 2006; 103: 10660-10665.
24. Chang DC, Xu N, Luo KQ. Degradation of cyclin B is required for the onset of anaphase in mammalian cells. J Biol Chem 2003; 278: 37865-37873.
25. Cross FR, Schroeder L, Kruse M, Chen KC. Quantitative characterization of a mitotic cyclin threshold regulating exit from mitosis. Mol Biol Cell 2005; 16: 2129-2138.
26. Parry DH, O'Farrell PH. The schedule of destruction of three mitotic cyclins can dictate the timing of events during exit from mitosis. Curr Biol 2001; 11: 671-683.
27. Sigrist S, Jacobs H, Stratmann R, Lehner CF. Exit from mitosis is regulated by Drosophila fizzy and the sequential destruction of cyclins A, B, and B3. EMBO J 1995; 14: 4827-4838.
28. Zachariae W, Nasmyth K. Whose end is destruction: cell division and the anaphase-promoting complex. Genes Dev 1999; 13: 2039-2058.
29. Chen F, Zhang Z, Bower J, Lu Y, Leonard SS, Ding M, et al. Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 2002; 99: 1990-1995.
30. Vecchione A, Croce CM, Baldassarre G. Fez1/Lzts1 a new mitotic regulator implicated in cancer development. Cell Div 2007; 2: 24.
31. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005; 8: 7-12.
32. Perez de Castro I, de Carcer G, Malumbres M. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis 2007; 28: 899-912.
33. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006; 38: 1043-1048.